PMS2 and colorectal cancer: In conclusion, using the P008-B1 PMS2 MLPA kit and a set of selected reference DNAs that are universally available, we identified deleterious PMS2 alterations in 23% of our PMS2-deficient colorectal cancer patients (27% of those undergoing first-line testing).